BioLineRx (BLRX) Current Deferred Revenue (2023)
BioLineRx has reported Current Deferred Revenue over the past 1 years, most recently at $13.0 million for Q4 2023.
- Quarterly results put Current Deferred Revenue at $13.0 million for Q4 2023, changed N/A from a year ago — trailing twelve months through Dec 2023 was $13.0 million (changed N/A YoY), and the annual figure for FY2023 was $13.0 million, changed.
- Current Deferred Revenue for Q4 2023 was $13.0 million at BioLineRx.
- Over the last five years, Current Deferred Revenue for BLRX hit a ceiling of $13.0 million in Q4 2023 and a floor of $13.0 million in Q4 2023.